Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

Eli Lilly (LLY-2.55%) is working to capture as much of that market as it can, ... As you'll see, that hope is a key theme in Eli Lilly's strategy for the obesity market.

LLY, NFLX, and GE lead today's top stock picks, with strong growth drivers but face headwinds from pricing, rivals, and costs ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Though Novo Nordisk and Eli Lilly are the giants in the GLP-1 boom, biotech execs say there are many more approaches and uses to be explored. Skip to Main Content Donald Trump ...

Shares of Eli Lilly And Co (NYSE: LLY) were climbing during Friday's trading session. The stock has been under pressure for the past three months, due to macro uncertainties and not ...

The acquisition aligns with Eli Lilly’s broader diversification strategy beyond its core diabetes and obesity treatment portfolio. Verve’s innovative gene-editing technology, which permanently ...

Some of the potential iterations of delivery methods Eli Lilly considered for orforglipron, at Eli Lilly’s headquarters in Indianapolis on March 31. The ultimate form has yet to be finalized.

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been making waves in the healthcare sector with its groundbreaking treatments for ...

Now, Eli Lilly and Co. is bracing for the onslaught. The Indianapolis-based company said Wednesday that its newest product, a drug for obesity called Zepbound, will be on pharmacy shelves shortly ...